Literature DB >> 10826762

Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature.

M T Yen1, D T Tse, X Wu, A H Wolfson.   

Abstract

PURPOSE: Because of previous reports of increased rate of recurrence and mortality after radiation therapy, eyelid sebaceous cell carcinoma has been considered radioresistant. Recent reports of success with primary radiation therapy have been attributed to advancements in irradiating technology and technique. Two cases of eyelid sebaceous cell carcinoma successfully treated with radiation therapy are reported. The techniques used are compared with the techniques described in previous reports, and factors favoring successful treatment are reevaluated.
METHODS: Case series and review of the literature. Two cases of eyelid sebaceous cell carcinoma that underwent radiation therapy are described. Both patients were offered, but refused, surgical excision. One patient received 69 Gy combined superficial and megavoltage x-ray irradiation to the left lower eyelid. The second patient received 59 Gy megavoltage electron beam irradiation to the right upper eyelid. A review of the literature was performed, and Fisher's exact test analysis was used to compare the results of all reported cases treated with < or =55 Gy with those treated with >55 Gy.
RESULTS: In both cases, the tumor responded to radiation therapy. One patient died 39 months after treatment, of myocardial infarction. The second patient is without clinical evidence of tumor recurrence 46 months after treatment. Fisher's exact test showed an advantage to patients treated with >55 Gy radiation (p = 0.05).
CONCLUSION: Radiation therapy with an appropriate delivery system is effective as a curative treatment for eyelid sebaceous cell carcinoma when >55 Gy of radiation dose is delivered. It should be considered for patients seeking an alternative to surgical excision.

Entities:  

Mesh:

Year:  2000        PMID: 10826762     DOI: 10.1097/00002341-200005000-00008

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  8 in total

1.  Sebaceous carcinoma of the eyelid: a rarity worth considering.

Authors:  Alexander Gardetto; Christian Rainer; Christian Ensinger; Ivo Baldissera; Hildegunde Piza-Katzer
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

Review 2.  Sebaceous Carcinoma: A Review of the Scientific Literature.

Authors:  Thomas Knackstedt; Faramarz H Samie
Journal:  Curr Treat Options Oncol       Date:  2017-08

3.  Neoadjuvant Systemic Chemotherapy in Sebaceous Gland Carcinoma of the Eyelid: A Retrospective Study.

Authors:  Saurav Verma; Nipun Kumar; Rachna Meel; Seema Sen; Seema Kashyap; Sanjay Sharma; Neelam Pushker; Deepam Pushpam; Sameer Bakhshi
Journal:  Ocul Oncol Pathol       Date:  2021-05-05

4.  Sebaceous Gland Carcinoma of Eyelid- A Tarnished Masquerade.

Authors:  Bijnya Birajita Panda; Sucheta Parija; Susanta Pujahari; Jyotiranjan Mallick
Journal:  J Clin Diagn Res       Date:  2016-04-01

5.  Surgical treatment of a solitary pulmonary metastasis from eyelid sebaceous carcinoma: report of a case.

Authors:  Kaoru Kaseda; Takashi Ohtsuka; Yuichiro Hayashi; Katsura Emoto; Keisuke Asakura; Ikuo Kamiyama; Taichiro Goto; Mitsutomo Kohno
Journal:  World J Surg Oncol       Date:  2014-04-23       Impact factor: 2.754

6.  Adnexal carcinomas of the head and neck.

Authors:  Jorge O Güerrissi; Juan Pablo Quiroga
Journal:  Indian J Plast Surg       Date:  2008-07

7.  Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy.

Authors:  Angela Orcurto; Béatrice E Gay; Wendy Jeanneret Sozzi; Michel Gilliet; Serge Leyvraz
Journal:  Case Rep Dermatol       Date:  2014-03-13

8.  Establishment and Characterization of a Novel Human Ocular Adnexal Sebaceous Carcinoma Cell Line.

Authors:  Andrew J Rong; Ryan A Gallo; Michelle G Zhang; Ravi Doddapaneni; Anthony J Griswold; John Y Lee; Stefan Kurtenbach; Sander R Dubovy; David T Tse; Daniel Pelaez
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.